Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Migraine Disorders

ClinicalTrials.gov lists 1,548 trials for Migraine Disorders or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 42.

MeSH D008881 Nervous System Diseases C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 97 Phase 1/2 Phase 1/2 12 Phase 2 Phase 2 141 Phase 2/3 Phase 2/3 22 Phase 3 Phase 3 227 Phase 4 Phase 4 164 Not applicable Not applicable 561 Observational Observational 322 Phase 1 Phase 1 97 Phase 1/2 Phase 1/2 12 Phase 2 Phase 2 141 Phase 2/3 Phase 2/3 22 Phase 3 Phase 3 227 Phase 4 Phase 4 164 Not applicable Not applicable 561 Observational Observational 322

Trials per phase (log scale)

1 more section with rows

1,484 of the 1,548 trials are tagged with Migraine Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Migraine Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Migraine Disorders trials start? (31)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 104

1994: 1 trials (Phase 1 1) 1995: 5 trials (Phase 3 5) 1998: 2 trials (Phase 3 2) 1999: 3 trials (Not applicable 2, Phase 2 1) 2000: 4 trials (Observational 2, Phase 3 2) 2001: 8 trials (Observational 2, Phase 4 1, Phase 3 4, Phase 2/3 1) 2002: 7 trials (Not applicable 3, Phase 4 1, Phase 3 1, Phase 2 2) 2003: 19 trials (Not applicable 3, Phase 4 2, Phase 3 9, Phase 2 4, Phase 1 1) 2004: 31 trials (Observational 3, Not applicable 5, Phase 4 6, Phase 3 12, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2005: 26 trials (Observational 3, Not applicable 1, Phase 4 5, Phase 3 10, Phase 2 6, Phase 1 1) 2006: 55 trials (Observational 6, Not applicable 16, Phase 4 6, Phase 3 14, Phase 2/3 1, Phase 2 10, Phase 1/2 1, Phase 1 1) 2007: 43 trials (Observational 4, Not applicable 12, Phase 4 3, Phase 3 10, Phase 2 9, Phase 1 5) 2008: 47 trials (Observational 7, Not applicable 6, Phase 4 5, Phase 3 6, Phase 2/3 1, Phase 2 11, Phase 1 11) 2009: 48 trials (Observational 11, Not applicable 7, Phase 4 8, Phase 3 9, Phase 2/3 1, Phase 2 10, Phase 1/2 1, Phase 1 1) 2010: 33 trials (Observational 6, Not applicable 7, Phase 4 9, Phase 3 4, Phase 2/3 2, Phase 2 2, Phase 1/2 1, Phase 1 2) 2011: 37 trials (Observational 7, Not applicable 17, Phase 4 4, Phase 3 3, Phase 2 2, Phase 1/2 1, Phase 1 3) 2012: 55 trials (Observational 8, Not applicable 21, Phase 4 4, Phase 3 8, Phase 2/3 2, Phase 2 7, Phase 1 5) 2013: 29 trials (Observational 3, Not applicable 13, Phase 4 5, Phase 3 2, Phase 2 2, Phase 1 4) 2014: 48 trials (Observational 7, Not applicable 17, Phase 4 10, Phase 3 1, Phase 2 6, Phase 1/2 1, Phase 1 6) 2015: 62 trials (Observational 13, Not applicable 26, Phase 4 6, Phase 3 9, Phase 2/3 1, Phase 2 1, Phase 1/2 1, Phase 1 5) 2016: 75 trials (Observational 7, Not applicable 28, Phase 4 10, Phase 3 14, Phase 2/3 2, Phase 2 6, Phase 1/2 2, Phase 1 6) 2017: 82 trials (Observational 9, Not applicable 34, Phase 4 4, Phase 3 9, Phase 2/3 5, Phase 2 12, Phase 1/2 1, Phase 1 8) 2018: 63 trials (Observational 16, Not applicable 24, Phase 4 3, Phase 3 7, Phase 2/3 1, Phase 2 6, Phase 1 6) 2019: 80 trials (Observational 14, Not applicable 26, Phase 4 12, Phase 3 16, Phase 2/3 1, Phase 2 5, Phase 1 6) 2020: 79 trials (Observational 16, Not applicable 31, Phase 4 12, Phase 3 13, Phase 2/3 1, Phase 2 4, Phase 1 2) 2021: 96 trials (Observational 21, Not applicable 42, Phase 4 6, Phase 3 13, Phase 2/3 1, Phase 2 8, Phase 1 5) 2022: 94 trials (Observational 25, Not applicable 34, Phase 4 14, Phase 3 16, Phase 2 3, Phase 1 2) 2023: 103 trials (Observational 37, Not applicable 42, Phase 4 6, Phase 3 8, Phase 2 3, Phase 1 7) 2024: 104 trials (Observational 44, Not applicable 36, Phase 4 8, Phase 3 6, Phase 2 7, Phase 1/2 1, Phase 1 2) 2025: 102 trials (Observational 23, Not applicable 55, Phase 4 7, Phase 3 8, Phase 2 5, Phase 1 4)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 96
2025 102
2024 104
2023 103
2022 94
2021 96
2020 79
2019 80
2018 63
2017 82

Showing 10 of 31 earlier years.

Start your 14-day trial Email me all 31 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 110 trials starting in 2026 and about 110 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 117 trials still running at the 2026-10-09 snapshot; registered median of 15 months across 995 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Migraine Disorders trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 97
Phase 1/2 12
Phase 2 141
Phase 2/3 22
Phase 3 227
Phase 4 164
Not applicable 561
Observational 322
Expanded access 2

How many Migraine Disorders trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 76
Recruiting 143
Enrolling by invitation 20
Active, not recruiting 34
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Migraine Disorders trials? (10)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 42
Eli Lilly and Company 30
GlaxoSmithKline 28
Allergan 25
Amgen 22

Showing 5 of 10 sponsors.

Start your 14-day trial Email me all 10 sponsors as a PDF

Which drugs are being tested for Migraine Disorders? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Eptinezumab 23
Galcanezumab 20
Atogepant 19
Fremanezumab 19
Lasmiditan 14

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Topiramate IR 46
Sumatriptan 5% 42
Erenumab PFS 39
Rimegepant/BHV3000 36
type A botulinum toxin 26

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Migraine Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Migraine 110 47
Appendicitis 55 37
Pneumonia 46 34
Abortion spontaneous 35 23
Syncope 32 24

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Migraine Disorders? (1,933)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Gepants for headache prevention in children and adolescents: A multicenter chart review study. Headache 2026 Yes
Intra-arterial lidocaine therapy via the middle meningeal artery for migraine headache: Theory, current practice and future directions. Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences 2026 Yes
Building a national headache medicine research network: The BE WELL with Migraine Champion Providers Network™. Headache 2026 Yes
Population Pharmacokinetics of Atogepant for the Prevention of Migraine. Clinical pharmacokinetics 2026 Yes
Fremanezumab in Children and Adolescents with Episodic Migraine. The New England journal of medicine 2026 Yes

Showing 5 of 1,933 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages